Heron Therapeutics In A Tough Spot After Cinvanti Court Loss (Rating Downgrade)
Heron Therapeutics hit as court invalidates key Cinvanti patents; Zynrelef can’t offset losses.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4913700-heron-therapeutics-in-a-tough-spot-after-cinvanti-court-loss-rating-downgrade"},"author":{"@type":"Person","name":"ONeil Trader","url":"https://seekingalpha.com/author/oneil-trader"},"publisher":{"@context":"https://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
